Related Experiment Video
Updated: Aug 6, 2026
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
PD-1/PD-L1 Expression Could Be a Prognostic Factor in Patients with Acute Myeloid Leukemia
Gizem Varkal1, Emel Gürkan2, Emine Kılıç Bağır3
1Department of Internal Medicine, Çukurova University Faculty of Medicine, Adana, Türkiye.
The Eurasian Journal of Medicine
|July 17, 2026
Summary
Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in acute myeloid leukemia (AML) was infrequent but associated with poorer survival. These findings suggest PD-1/PD-L1 may indicate poor prognosis in AML patients.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Investigating programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression patterns in acute myeloid leukemia (AML).
- Determining the prevalence and prognostic significance of PD-1 and PD-L1 in AML patients.
Purpose of the Study:
- To evaluate the expression of PD-1 and PD-L1 in AML.
- To correlate PD-1/PD-L1 expression with clinical characteristics and survival outcomes in AML.
Main Methods:
- Retrospective analysis of 99 AML patients.
- Immunohistochemical assessment of PD-1 and PD-L1 expression in bone marrow biopsy samples.
- Correlation analysis with clinical data, treatment response, and survival.
Main Results:
- PD-1/PD-L1 positivity (≥ 5%) was found in 9.1% of AML patients.
- PD-1/PD-L1 expression correlated with lower hemoglobin levels at diagnosis.
- Elevated PD-1/PD-L1 expression was associated with significantly poorer overall survival (11 months vs. 24 months).
Conclusions:
- PD-1/PD-L1 expression is relatively infrequent in AML but linked to worse survival outcomes.
- PD-1/PD-L1 may serve as a prognostic factor in AML.
- Larger studies are warranted to confirm the prognostic relevance of PD-1/PD-L1 in AML.
